Skip to main content
SpringerLink
Log in

Treatment of Spasmodic Dysphonia with Botulinum Toxin: Clinical Experiences and Research Issues

  • Chapter
Botulinum and Tetanus Neurotoxins

  • 198 Accesses

Abstract

Spasmodic Dysphonia is a disabling speech disorder characterized by excessive contractions of laryngeal muscles. Botulinum toxin has been demonstrated in several clinical trials to be very effective in improving speech in most patients and its clinical use is becoming more widespread. Although the benefits of botulinum toxin treatment are considerable, few patients achieve a totally normal voice and minor side effects are common. Clinical research is needed to determine the factors limiting improvement, to determine the role of adjunctive speech therapy, and to develop treatment protocols which will maximize benefits and diminish side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams RD, Victor M. Principles of Neurology, 4th ed. New York: McGraw-Hill, 1989: 62–67.

    Google Scholar 

  2. Arnold GE. Spastic dysphonia: I. Changing interpretations of a persistent affliction. Logos 1959; 2: 314.

    Google Scholar 

  3. Aronson AE, Brown JR, Litin EM, et al. Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects. J Speech Hear Disord 1968; 33: 203–218.

    PubMed  CAS  Google Scholar 

  4. Aronson AE, Brown JR, Litin EM, et al. Spastic dysphonia II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord 1968; 33: 219–231.

    PubMed  CAS  Google Scholar 

  5. Aronson AE, Hartman DE. Adductor spastic dysphonia as a sign of essential (voice) tremor. J Speech Hear Disord 1981; 46: 52–56.

    PubMed  CAS  Google Scholar 

  6. Aronson AE. Psychogenic voice disorders: an interdisciplinary approach to detection, diagnosis and therapy. In: Audio Seminars in Speech Therapy. Philadelphia: Saunders, 1973.

    Google Scholar 

  7. Blitzer A, Brin M, Fahn S, Lovelace RE. Clinical characteristics of focal laryngeal dystonia: Study of 110 cases. Laryngoscope 1988; 98: 636–640.

    Article  PubMed  CAS  Google Scholar 

  8. Blitzer A, Brin MF, Stewart C, Aviv J, Fahn, S. Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope 1992; 102: 163–167.

    Article  PubMed  CAS  Google Scholar 

  9. Cannito M, Johnson J. Spastic dysphonia: A continuum disorder. J. Commun Dis 1981; 14: 215–223.

    Article  CAS  Google Scholar 

  10. Dedo HH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhino] Laryngol 1976; 85: 451–59.

    CAS  Google Scholar 

  11. Ford CN. A multipurpose laryngeal injector device. Otolaryngol Head Neck Surg 1990; 103: 135–137.

    PubMed  CAS  Google Scholar 

  12. Freeman F, Cannito MP, Finitzo-Hieber T. Classification of Spasmodic Dysphonia by PerceptualAcoustic-Visual Means. Spastic dysphonia: State of the Art 1984. New York: The Voice Foundation, 1984: 5–13.

    Google Scholar 

  13. Ludlow CL, Naunton RF, Sedory MA, Schulz MA, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988; 38:1220-122?

    Google Scholar 

  14. Ludlow CL, Hallett M, Sedory SE et al. The Pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Beradelli A, Benecke R, eds. Motor Disturbances I I. London: Academic Press, 1990.

    Google Scholar 

  15. Miller RH, Woodson GE, Jancovic J. Botulinum toxin injection of the vocal for spasmodic dysphonia. Arch Otol Laryngol Head Neck Surg 1987; 113: 603–605.

    Article  CAS  Google Scholar 

  16. Rabuzzi DD, McCall GN. Spasmodic dysphonia: A clinical perspective. Trans Am Acad Ophthalmol Otolaryngol 1972; 76: 724–728.

    PubMed  CAS  Google Scholar 

  17. Robe E, Brulik J, Moore, P. A study of spastic dysphonia. Neurologic and electroencephalographic abnormalities. Laryngoscope 1960; 50: 219–245.

    Google Scholar 

  18. Rosenfield DB, Donovan DT, Sulek M, Viswanath NS, Inbody GP, Nudelman HB. Neurologic aspects of spasmodic dysphonia. J Otolaryngology 1990; 19: 231–236.

    CAS  Google Scholar 

  19. Schaefer S. Neuropathology of spasmodic dysphonia. Laryngoscope 1983; 93: 1183–1204.

    PubMed  CAS  Google Scholar 

  20. Truong EE, Rontal M, Rolnick M et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991; 101: 630–634.

    Article  Google Scholar 

  21. Woodson GE, Zwimer P, Murry T, Swenson M. Use of flexible laryngoscopy to classify patients with spasmodic dysphonia. J Voice 1991; 5: 85–91.

    Article  Google Scholar 

  22. Woodson GE, Murry T, Zwimer P, Swenson M. Assessment of patients with spasmodic dysphonia. J Voice 1992, in press.

    Google Scholar 

  23. Zwimer P, Murry T, Swenson M, Woodson G. Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J Voice 1991; 5: 78–84.

    Article  Google Scholar 

  24. Zwimer P, Murry T, Woodson G. Phonatory function of neurologically impaired patients. J Commun Dis 1991; 24: 287–300.

    Article  Google Scholar 

  25. Zwimer P, Murry T, Woodson G. Effects of botulinum toxin therapy in patients with spasmodic dysphonia: Acoustic, aerodynamic, and videoendoscopic findings Laryngoscope 1992; 102: 400406.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery/Division of Otolaryngology, University of California, San Diego School of Medicine and VA Medical Center, San Diego, 225 Dickinson Street, 9112C, San Diego, CA, 92103, USA

    Gayle E. Woodson & Thomas Murry

  2. HNO Klinik, Klinikum Grosshadern, Marchiainistr. 15, 8000, Munich 70, Germany

    Petra Zwirner

  3. Department of Neurosciences, University of California, San Diego School of Medicine, 225 Dickinson Street, San Diego, CA, 92103, USA

    Michael Swenson

Authors
  1. Gayle E. Woodson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Murry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petra Zwirner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Swenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Wisconsin, Madison, Wisconsin, USA

    Bibhuti R. DasGupta

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Woodson, G.E., Murry, T., Zwirner, P., Swenson, M. (1993). Treatment of Spasmodic Dysphonia with Botulinum Toxin: Clinical Experiences and Research Issues. In: DasGupta, B.R. (eds) Botulinum and Tetanus Neurotoxins. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9542-4_68

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9542-4_68

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9544-8

  • Online ISBN: 978-1-4757-9542-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation